Pharmacokinetic Drug Interactions with ACE Inhibitors

  title={Pharmacokinetic Drug Interactions with ACE Inhibitors},
  author={Hiroshi Shionoiri},
  journal={Clinical Pharmacokinetics},
  • H. Shionoiri
  • Published 1 July 1993
  • Medicine, Biology
  • Clinical Pharmacokinetics
SummaryAngiotensin converting enzyme (ACE) inhibitors which have active moieties excreted mainly in urine require adjustment of either the dose or the interval between doses in patients with moderate to severe renal dysfunction or severe congestive heart failure. Those agents such as temocapril (CS 622) and fosinopril, excreted both in urine and bile, may not require such adjustment. Renal clearance of ACE inhibitors may be reduced and some accumulation may occur in elderly patients with mild… 
Optimal Dosage of ACE Inhibitors in Older Patients
It is safer to use lower initial dosages of ACE inhibitors in elderly hypertensive patients because hypotensive reactions are not always predictable and it is necessary to interrupt diuretic treatment for a few days to prevent severe hypotension.
Etiology and Treatment of Angiotensin Converting Enzyme Inhibitor-Induced Cough
ABSTRACT Angiotensin-converting enzyme inhibitors (ACEls) are widely used in the treatment of hypertension and congestive heart failure (CHF). They have also been shown to slow the progression of
Fosinopril. Clinical pharmacokinetics and clinical potential.
The available evidence suggests that the pharmacokinetic variables of fosinoprilat in patients receiving haemodialysis were similar to those in patients with moderate to severe renal dysfunction, and thus dosage modifications or supplemental dose administration following dialysis may be unnecessary.
ACE Inhibitors and the Kidney
Patients at the greatest risk for renal adverse effects (those with heart failure, diabetes mellitus and/or chronic renal failure) also can expect the greatest benefit from ACE inhibitors, but dosages should be carefully titrated, with monitoring of renal function and serum potassium levels.
Drug interactions with angiotensin receptor blockers
Compared to other classes of antihypertensive agents, the ARBs appear to have a low potential for drug interactions; however, interactions with this class occur and variations within the class have been detected, mainly due to different affinities for cytochrome P450 isoenzymes.
Interaction Studies of ACE Inhibitors with Antidiabetic Drugs
  • S. Naveed, H. Sadia
  • Medicine, Biology
    Metformin - Pharmacology and Drug Interactions [Working Title]
  • 2021
Investigation of the “in vitro” interactions of ACE inhibitors with frequently prescribed and co-administered drugs in simulated human body environments revealed that the availability of enalapril was not affected in presence of antidiabetic drugss whereas theavailability of captopril and lisinopril were altered in presenceof NIDDMs.
Drug Interactions with Irbesartan
Irbesartan has demonstrated minimal potential for drug or food interactions in trials conducted to date, and Fluconazole did increase the steady-state peak plasma concentration and area under the concentration-time curve, but these increases are not likely to be clinically significant.
Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension.
Evaluating whether an ACE inhibitor, temocapril, could modify the urinary microalbumin excretion rate (UAE) in hypertensive outpatients who had no signs of renal impairment indicates that long-term therapy with temocAPril may be superior in reducing UAE than is diuretic therapy in patients with essential hypertension.
parison of Long-Term Therapeutic Effect ACE Inhibitor, Ternocapril, with That of a Diuretic on Microalburninuria in Non-Diabetic Essential Hypertension
Evaluating whether an ACE inhibitor, temocapril, could modify the urinary microalbumin excretion rate (UAE) in hypertensive outpatients who had no signs of renal impairment indicates that long-term therapy with temocol may be superior in reducing UAE than is diuretic therapy in patients with essential hypertension.


Pharmacokinetic Optimisation of Angiotensin Converting Enzyme (ACE) Inhibitor Therapy
Among the pharmacokinetic characteristics of ACE inhibitors the route of excretion and to a lesser degree the half-life appear to be the most clinically relevant and there is no evidence that being a prodrug offers a significant clinical advantage.
Clinical Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitors
The available data suggest that enalapril's pharmacokinetic properties in patients with congestive heart failure resemble those in healthy subjects, however, additional data are necessary to confirm this.
Nephrotoxicity Associated With Concomitant ACE Inhibitor and NSAID Therapy
Significant nephrotoxicity during the concomitant use of ACE inhibitors and NSAIDs is not uncommon, and attention should be drawn to this potentially important interaction.
Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension.
The combination of converting enzyme inhibitor and diuretic provides an ideal choice in terms of efficacy, compliance, side effects, and cost.
Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Enalapril 10 to 40 mg/day administered either once or twice daily is effective in lowering blood pressure in all grades of essential and renovascular hypertension, and shows similar efficacy to usual therapeutic dosages of hydrochlorothiazide, beta-blockers and captopril.
The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure, especially when efforts are made to block the formation of angiotensin (Ang) II continuously.
Metabolic effects of ACE inhibitors.
  • C. Berne
  • Medicine, Biology
    Journal of internal medicine. Supplement
  • 1991
It remains to be established whether this effect of captopril can be extrapolated to other ACE inhibitors, and the extent to which effects on insulin sensitivity will influence the long-term consequences for future risk of diabetes mellitus and coronary heart disease in patients with essential hypertension.
Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function.
It is suggested that cilazapril has a long-lasting action and that it is a useful antihypertensive agent for controlling blood pressure in patients with either NRF or IRF.
Clinical Pharmacokinetics of β-Adrenoceptor Blocking Drugs
SummaryAll β-adrenoreceptor blocking drugs seem to be fairly rapidly and completely absorbed from the gastro-intestinal tract. The rate of absorption, however, appears to be lower in elderly patients